Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Liabilities and Shareholders Equity (2018 - 2025)

Summit Therapeutics (SMMT) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $261.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 47.95% year-over-year to $261.7 million, compared with a TTM value of $969.6 million through Dec 2025, down 33.46%, and an annual FY2024 reading of $435.6 million, up 114.62% over the prior year.
  • Liabilities and Shareholders Equity was $261.7 million for Q3 2025 at Summit Therapeutics, down from $324.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $664.2 million in Q4 2022 and bottomed at $95.7 million in Q2 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $257.9 million, with a median of $218.5 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 485.82% in 2022, then plummeted 69.44% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $113.4 million in 2021, then surged by 485.82% to $664.2 million in 2022, then tumbled by 69.44% to $202.9 million in 2023, then surged by 114.62% to $435.6 million in 2024, then plummeted by 39.91% to $261.7 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for SMMT at $261.7 million in Q3 2025, $324.0 million in Q2 2025, and $383.8 million in Q1 2025.